Bob Pooler, an analyst with Zurich-based investment bank Lombard Odier Darier Hentsch, offered similar comments, saying, "The discontinuation of NKS104 was widely anticipated due to the emergence of liver enzyme elevations and the lack of a major clinical differentiation over AstraZeneca's superstatin Crestor."
Link: NOVARTIS HALTS DEVELOPMENT OF CHOLESTEROL-LOWERING DRUG.
Recent Comments